相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cystatin C-Based Equation to Estimate GFR without the Inclusion of Race and Sex
H. Pottel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
Alberto Ortiz et al.
CLINICAL KIDNEY JOURNAL (2023)
Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association
Connie W. Tsao et al.
CIRCULATION (2022)
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. Van der Aart-van der Beek et al.
NATURE REVIEWS NEPHROLOGY (2022)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L. J. Visseren et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors
Pensiri Choosongsang et al.
DIABETIC MEDICINE (2022)
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
Arnaud D. Kaze et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease
Michele Provenzano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Cystatin C-based estimated GFR performs best in identifying individuals with poorer survival in an unselected Chinese population: results from the China Health and Retirement Longitudinal Study (CHARLS)
Cheng Zhu et al.
CLINICAL KIDNEY JOURNAL (2022)
Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics
Edmund Y. M. Chung et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
Runzhou Pan et al.
PLOS ONE (2022)
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses
Liam Gaziano et al.
CIRCULATION (2022)
Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials
Wan-Chuan Tsai et al.
BMJ OPEN (2022)
Assessment of Cystatin C Level for Risk Stratification in Adults With Chronic Kidney Disease
Jennifer S. Lees et al.
JAMA NETWORK OPEN (2022)
Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR
Debbie C. Chen et al.
KIDNEY360 (2022)
Sarcopenia in chronic kidney disease: what have we learned so far?
Alice Sabatino et al.
JOURNAL OF NEPHROLOGY (2021)
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review
Oliver Darlington et al.
ADVANCES IN THERAPY (2021)
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Michael G. Shlipak et al.
KIDNEY INTERNATIONAL (2021)
Assessment of kidney function: clinical indications for measured GFR
Natalie Ebert et al.
CLINICAL KIDNEY JOURNAL (2021)
Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options
Joachim Jankowski et al.
CIRCULATION (2021)
Race, Genetic Ancestry, and Estimating Kidney Function in CKD
C. Hsu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk of a future first-ever myocardial infarction in women
Elisabet Soderstrom et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2021)
The Shrunken pore syndrome is associated with poor prognosis and lower quality of life in heart failure patients: the HARVEST-Malmo study
Liana Xhakollari et al.
ESC HEART FAILURE (2021)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
Adrian Post et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Yuka Goto et al.
ENDOCRINE CONNECTIONS (2020)
Shrunken pore syndrome - a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options
Anders Grubb
CLINICAL BIOCHEMISTRY (2020)
Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science
Alessia Lena et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project
Dietrich Rothenbacher et al.
BMC MEDICINE (2020)
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
Takashi Sasaki et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Atherosclerosis in Chronic Kidney Disease More, Less, or Just Different?
Jose M. Valdivielso et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
Jennifer S. Lees et al.
NATURE MEDICINE (2019)
Evaluation of discriminative capacity of two formulas of CKD-EPI to predict complications after the first episode of heart failure with preserved ejection fraction
Dmitry Shchekochikhin et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2019)
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Seigo Sugiyama et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Teruki Miyake et al.
OPEN MEDICINE (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
Jiang He et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Cardiovascular Health in African Americans A Scientific Statement From the American Heart Association
Mercedes R. Carnethon et al.
CIRCULATION (2017)
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Ryotaro Bouchi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy
Chiho Yamamoto et al.
ENDOCRINE JOURNAL (2016)
Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism
Ana Huerta et al.
JOURNAL OF HYPERTENSION (2016)
The heart and vascular system in dialysis
Christoph Wanner et al.
LANCET (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cause of Death in Patients with Reduced Kidney Function
Stephanie Thompson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C
Elisabet Zamora et al.
CLINICAL CHEMISTRY (2014)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
Michael G. Shlipak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C
Lesley A. Inker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications
Carmen A. Peralta et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
Andrew S. Levey et al.
KIDNEY INTERNATIONAL (2011)
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
Charles A. Herzog et al.
KIDNEY INTERNATIONAL (2011)
Ethnicity-Related Skeletal Muscle Differences Across the Lifespan
Analiza M. Silva et al.
AMERICAN JOURNAL OF HUMAN BIOLOGY (2010)
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Kunihiro Matsushita et al.
LANCET (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Cystatin C and risk of heart failure in the Physicians' Health Study (PHS)
Luc Djousse et al.
AMERICAN HEART JOURNAL (2008)
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease
Michael G. Shlipak et al.
ANNALS OF INTERNAL MEDICINE (2006)
Cystatin C concentration as a risk factor for heart failure in older adults
MJ Sarnak et al.
ANNALS OF INTERNAL MEDICINE (2005)
Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community
G Manjunath et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis
VR Dharnidharka et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)